-
1دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
2دورية أكاديمية
المؤلفون: Engle SM; Eli Lilly and Company, Indianapolis, IN, USA., Chang CY; Eli Lilly and Company, Indianapolis, IN, USA., Ulrich BJ; Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA.; Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA., Satterwhite A; Eli Lilly and Company, Indianapolis, IN, USA., Hayes T; Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA.; Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA., Robling K; Eli Lilly and Company, Indianapolis, IN, USA., Sissons SE; Eli Lilly and Company, Indianapolis, IN, USA., Schmitz J; Eli Lilly and Company, Indianapolis, IN, USA., Tepper RS; Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA., Kaplan MH; Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA.; Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA., Sims JT; Eli Lilly and Company, Indianapolis, IN, USA.
المصدر: Clinical and experimental immunology [Clin Exp Immunol] 2021 Nov 30. Date of Electronic Publication: 2021 Nov 30.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 0057202 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2249 (Electronic) Linking ISSN: 00099104 NLM ISO Abbreviation: Clin Exp Immunol Subsets: MEDLINE
-
3دورية أكاديمية
المؤلفون: Sims JT; Eli Lilly and Company, Indianapolis, IN, USA., Chang CY; Eli Lilly and Company, Indianapolis, IN, USA., Higgs RE; Eli Lilly and Company, Indianapolis, IN, USA., Engle SM; Eli Lilly and Company, Indianapolis, IN, USA., Liu Y; Eli Lilly and Company, Indianapolis, IN, USA., Sissons SE; Eli Lilly and Company, Indianapolis, IN, USA., Rodgers GH; Eli Lilly and Company, Indianapolis, IN, USA., Simpson EL; Department of Dermatology, Oregon Health & Science University, Portland, OR, USA., Silverberg JI; Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA., Forman SB; Forward Clinical Trials, Inc, Tampa, FL, USA., Janes JM; Eli Lilly and Company, Indianapolis, IN, USA., Colvin SC; Eli Lilly and Company, Indianapolis, IN, USA., Guttman-Yassky E; Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
المصدر: Experimental dermatology [Exp Dermatol] 2021 Nov; Vol. 30 (11), pp. 1650-1661. Date of Electronic Publication: 2021 Jun 09.
نوع المنشور: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Validation Study
بيانات الدورية: Publisher: Munksgaard Country of Publication: Denmark NLM ID: 9301549 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0625 (Electronic) Linking ISSN: 09066705 NLM ISO Abbreviation: Exp Dermatol Subsets: MEDLINE
مواضيع طبية MeSH: Azetidines/*therapeutic use , Dermatitis, Atopic/*blood , Dermatitis, Atopic/*drug therapy , Purines/*therapeutic use , Pyrazoles/*therapeutic use , Sulfonamides/*therapeutic use, Adult ; Biomarkers/blood ; Dermatitis, Atopic/complications ; Female ; Humans ; Male ; Middle Aged ; Severity of Illness Index ; Young Adult
-
4دورية أكاديمية
المؤلفون: Patel DR; Clinical Services, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA., Urva S; Global PK/PD & Pharmacometrics, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA., Ho S; Translational Sciences - Autoimmunity, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA., Buckman CJ; Immunology Discovery Research, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA., Ma Y; Immunology Discovery Research, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA., Lim J; Global PK/PD & Pharmacometrics - SG, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA., Sissons SE; Translational Sciences - Autoimmunity, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA., Zuniga MS; Translational Sciences - Autoimmunity, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA., Philips D; Clinical Pharmacology, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA., Cox K; Translational Sciences - Autoimmunity, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA., Dairaghi DJ; Immunology Discovery Research, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA.
المصدر: Clinical and translational science [Clin Transl Sci] 2021 May; Vol. 14 (3), pp. 1037-1048. Date of Electronic Publication: 2021 Feb 13.
نوع المنشور: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE
مواضيع طبية MeSH: Drugs, Investigational/*pharmacology , Phosphodiesterase 4 Inhibitors/*pharmacology, Administration, Oral ; Adult ; Animals ; Cross-Over Studies ; Cyclic Nucleotide Phosphodiesterases, Type 4/metabolism ; Drug Evaluation, Preclinical ; Drugs, Investigational/therapeutic use ; Enzyme Assays ; Female ; Healthy Volunteers ; Humans ; Macaca mulatta ; Male ; Mice ; Middle Aged ; Phosphodiesterase 4 Inhibitors/therapeutic use ; Psoriasis/drug therapy ; Thalidomide/analogs & derivatives ; Thalidomide/pharmacology ; Thalidomide/therapeutic use
-
5دورية أكاديمية
المؤلفون: Huang G; Section of Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Brigham and Women's Hospital-Harvard Medical School, Boston, Massachusetts., Rocha GV; Eli Lilly and Co., Indianapolis, Indiana., Pencina KM; Section of Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Brigham and Women's Hospital-Harvard Medical School, Boston, Massachusetts., Cox K; Eli Lilly and Co., Indianapolis, Indiana., Krishnan V; Eli Lilly and Co., Indianapolis, Indiana., Henriksen K; Department of Endocrinology, Nordic Bioscience Biomarkers & Research, Herlev Hovedgade, Herlev, Denmark., Mitchell P; Eli Lilly and Co., Indianapolis, Indiana., Sissons SE; Eli Lilly and Co., Indianapolis, Indiana., Li Z; Section of Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Brigham and Women's Hospital-Harvard Medical School, Boston, Massachusetts., Nedergaard AF; Department of Endocrinology, Nordic Bioscience Biomarkers & Research, Herlev Hovedgade, Herlev, Denmark., Karsdal MA; Department of Endocrinology, Nordic Bioscience Biomarkers & Research, Herlev Hovedgade, Herlev, Denmark., Sun S; Department of Endocrinology, Nordic Bioscience Biomarkers & Research, Herlev Hovedgade, Herlev, Denmark., Storer TW; Section of Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Brigham and Women's Hospital-Harvard Medical School, Boston, Massachusetts., Basaria S; Section of Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Brigham and Women's Hospital-Harvard Medical School, Boston, Massachusetts., Bhasin S; Section of Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Brigham and Women's Hospital-Harvard Medical School, Boston, Massachusetts.
المصدر: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2019 Sep 01; Vol. 104 (9), pp. 3768-3778.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication Model: Print Cited Medium: Internet ISSN: 1945-7197 (Electronic) Linking ISSN: 0021972X NLM ISO Abbreviation: J Clin Endocrinol Metab Subsets: PubMed not MEDLINE; MEDLINE
-
6دورية أكاديمية
المؤلفون: Poorbaugh J; Immunology Discovery, Eli Lilly and Company, Indianapolis, IN 46285, USA. Electronic address: JPoorbaugh@lilly.com., Samanta T; Immunology Discovery, Eli Lilly and Company, Indianapolis, IN 46285, USA., Bright SW; Immunology Discovery, Eli Lilly and Company, Indianapolis, IN 46285, USA., Sissons SE; Immunology Discovery, Eli Lilly and Company, Indianapolis, IN 46285, USA., Chang CY; Immunology Discovery, Eli Lilly and Company, Indianapolis, IN 46285, USA., Oberoi P; Meso Scale Diagnostics, Rockville, MD 20850, USA., MacDonald AJ; Immunology Discovery, Eli Lilly and Company, Indianapolis, IN 46285, USA., Martin AP; Immunology Discovery, Eli Lilly and Company, Indianapolis, IN 46285, USA., Cox KL; Immunology Discovery, Eli Lilly and Company, Indianapolis, IN 46285, USA., Benschop RJ; Immunology Discovery, Eli Lilly and Company, Indianapolis, IN 46285, USA.
المصدر: Journal of immunological methods [J Immunol Methods] 2019 Mar; Vol. 466, pp. 9-16. Date of Electronic Publication: 2018 Dec 24.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 1305440 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7905 (Electronic) Linking ISSN: 00221759 NLM ISO Abbreviation: J Immunol Methods Subsets: MEDLINE
مواضيع طبية MeSH: Enzyme-Linked Immunosorbent Assay*, Interleukins/*blood, Healthy Volunteers ; Humans ; Interleukins/immunology
-
7دورية أكاديمية
المؤلفون: Yin T; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Lallena MJ; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Kreklau EL; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Fales KR; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Carballares S; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Torrres R; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Wishart GN; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Ajamie RT; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Cronier DM; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Iversen PW; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Meier TI; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Foreman RT; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Zeckner D; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Sissons SE; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Halstead BW; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Lin AB; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Donoho GP; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Qian Y; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Li S; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Wu S; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Aggarwal A; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Ye XS; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Starling JJ; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Gaynor RB; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., de Dios A; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom du_jian@lilly.com de_dios_alfonso@lilly.com., Du J; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom du_jian@lilly.com de_dios_alfonso@lilly.com.
المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2014 Jun; Vol. 13 (6), pp. 1442-56. Date of Electronic Publication: 2014 Mar 31.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
مواضيع طبية MeSH: Antineoplastic Agents/*administration & dosage , Apoptosis/*drug effects , Cyclin-Dependent Kinase 9/*genetics , Cyclohexylamines/*administration & dosage , Indazoles/*administration & dosage , Leukemia/*drug therapy, Cell Line, Tumor ; Cyclin-Dependent Kinase 9/antagonists & inhibitors ; Humans ; Leukemia/pathology ; Myeloid Cell Leukemia Sequence 1 Protein/biosynthesis ; Phosphorylation/drug effects ; Serine/metabolism